Tempest Therapeutics Advances Liver Cancer Program with Roche Collaboration and FDA Agreement
Key Insights
Tempest Therapeutics has secured a drug supply agreement with Roche for its Phase 3 study in first-line Hepatocellular Carcinoma (search) (1L HCC (search)).
The FDA has agreed to Tempest's Phase 3 study plan, including dosing and overall survival (OS) as the primary endpoint, potentially shortening the timeline with an early efficacy analysis.
Tempest Therapeutics estimates the Phase 3 study will cost around $100 million, but the Roche agreement is expected to reduce expenses by $30-50 million.
Tempest Therapeutics is making significant strides in its development of cancer treatments, particularly in Hepatocellular Carcinoma (search) (HCC (search)). The company has entered into a drug supply agreement with Roche for its upcoming Phase 3 study in first-line HCC, a move that underscores the growing confidence in Tempest's therapeutic approach. This collaboration and recent regulatory achievements signal a pivotal moment for the biotechnology firm as it advances its clinical program.
FDA Agreement on Phase 3 Study Plan
Tempest Therapeutics recently concluded a successful End of Phase 2 (EOP2) meeting with the FDA, securing agreement on the Phase 3 study plan. The agreed-upon plan includes the dosing schedule and overall survival (OS) as the primary endpoint. Notably, the FDA has also approved the statistical plan, which incorporates an early efficacy analysis. This could potentially reduce the study's timeline to primary analysis by up to eight months, accelerating the path to potential regulatory approval.
Strategic Drug Supply Agreement with Roche
The drug supply agreement with Roche is a significant development for Tempest Therapeutics. By partnering with Roche, Tempest aims to reduce the financial burden of the Phase 3 study. The company estimates that the Roche agreement could decrease expenses by $30-50 million, assuming at least 700 subjects are enrolled in the study. This collaboration not only provides financial relief but also validates Tempest's scientific approach in the competitive landscape of cancer therapeutics.
Financial Considerations and Market Performance
Despite these positive developments, Tempest Therapeutics acknowledges the need for substantial funding to support the Phase 3 study, with estimated costs around $100 million. This financial requirement comes at a time when the company's stock, under the ticker TPST (Ovascience Inc), has faced market challenges, recently hitting a 52-week low. Investors are closely monitoring TPST's performance as it navigates these financial waters, hoping for a strategy that could reverse the downward trend and restore confidence in the stock's potential for recovery.
Analyst Confidence
Despite the financial challenges, several analysts remain optimistic about Tempest Therapeutics' prospects. H.C. Wainwright reaffirmed its Buy rating and $47.00 stock price target for Tempest Therapeutics following the FDA agreement. Similarly, Scotiabank reiterated its Sector Outperform rating on shares of Tempest Therapeutics, reflecting confidence in the company's strategic position and the expected swift patient recruitment for its clinical program for hepatocellular carcinoma (search) treatment.
Leadership Changes
As Tempest Therapeutics prepares for the upcoming trials, the company has appointed Troy M. Wagner as Vice President of Quality Assurance. This strategic move underscores Tempest's commitment to maintaining high standards of quality and compliance as it advances its clinical programs.